The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …

A single biomarker is not adequate to identify patients with gastric cancer (GC) who have the
potential to benefit from anti-PD-1/PD-L1 therapy, presumably owing to the complexity of the …

Interaction between tumor cells and immune cells in the tumor microenvironment is
important in cancer development. Immune cells interact with the tumor cells to shape this …

Background Deciphering intra‐and inter‐tumoural heterogeneity is essential for
understanding the biology of gastric cancer (GC) and its metastasis and identifying effective …

Chimeric antigen receptor (CAR) T cell therapy has limited efficacy against solid tumors, and
one major challenge is T cell exhaustion. To address this challenge, we performed a …

Background CD8+ T cells differentiate into exhausted status within tumors, including
hepatocellular carcinoma (HCC), which constitutes a solid barrier to effective anti-tumor …

Background & Aims Despite recent translation of immunotherapies into clinical practice, the
immunobiology of hepatocellular carcinoma (HCC), in particular the role and clinical …

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the
leading causes of cancer-related death worldwide. Advanced HCC displays strong …

T-cell exhaustion denotes a hypofunctional state of T lymphocytes commonly found in
cancer, but how tumor cells drive T-cell exhaustion remains elusive. Here, we find T-cell …